January 30, 2020 Aprea Therapeutics Receives FDA Breakthrough Therapy Designation for APR-246 in Combination with Azacitidine for the Treatment of Myelodysplastic Syndromes (MDS) with a TP53 Mutation
January 29, 2020 Promising results from human PK study assessing novel ketorolac formulations for treatment of pain
January 21, 2020 Targovax announces encouraging data in mesothelioma study combining ONCOS-102 and standard of care chemotherapy
January 21, 2020 GenSight Biologics Reports its Cash Position as of December 31, 2019 and Provides Operational Update